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A fluorescent histone deacetylase (HDAC)
inhibitor for cellular imaging†
Cassandra L. Fleming,a Trent D. Ashton,a Cameron Nowell,b Mark Devlin,c
Anthony Natoli,c Jeannette Schreudersc and Frederick M. Pfeﬀer*a
Fluorescence microscopy studies using 4-morpholinoscriptaid (4MS)
demonstrated rapid cellular uptake of this scriptaid analogue into
the cytoplasm but no nuclear penetration. As 4MS and scriptaid have
the same in vitro activity against HDACs and KASUMI-1 cells; 4MS
exemplifies a rational approach to subtly modify ‘profluorogenic’
substrates for intracellular studies.
Fluorescent tagging of bioactives for cell based microscopy
studies is conventionally achieved by conjugating, by means
of a spacer, a bulky fluorophore to the drug of interest.1 While
fluorescent, the extraneous conjugation to a fluorophore invari-
ably leads to an increase in molecular weight and has an impact
on c log P—parameters that medicinal chemists spend con-
siderable eﬀort optimising. Indeed, the behaviour of the
‘tagged’ compound in cells might not accurately reflect that of
the parent.
Ideally, only subtle structural modifications would be performed
on a bioactive to render it fluorescent. Despite the seemingly
obvious benefits of such an approach, no examples could be
found.‡ While this strategy is limited somewhat in that only
aromatic compounds can be considered, the dominance of highly
aromatic scaﬀolds in drug discovery makes it complementary
to the conventional ‘tagging’ approach. A bioactive that is identi-
fied as being structurally related to an existing fluorophore
might be termed ‘profluorogenic’; for example naphthalene is a
common component of biologically active compounds2 and is
the core of several highly fluorescent entities including the
4-aminonaphthalimides.3
Scriptaid (1, Fig. 1) is a well-studied histone deacetylase
(HDAC) inhibitor with established anticancer activity.4,5 More
recently, scriptaid (1) has also been shown to have beneficial
eﬀects in the treatment of HIV and neurodegenerative disorders.6
Scriptaid (1) possesses the typical pharmacophore of HDAC
inhibitors which includes (i) zinc binding group (chelates the
Zn2+ ion of the active site, see Fig. 1) (ii) linker (occupies a
hydrophobic tunnel) which connects to the (iii) capping group
(solvent exposed).7
Recognising the structural similarities of the 4-amino-1,8-
naphthalimide fluorophore and the known HDAC inhibitor
scriptaid (1), the fluorescent scriptaid analogue 4MS was developed
(Fig. 1); the key feature being the introduction of the relatively
small 4-morpholino substituent (MW = 87).
While SAR studies of scriptaid do not extend to modifications
of the capping group, we reasoned that, given the non-critical
role of the capping group with respect to HDAC inhibition,
introduction of a small amino moiety would not have deleterious
eﬀects on HDAC activity. Indeed, calculated properties (c log P
and PSA) of scriptaid (1) and 4MS showed only subtle diﬀer-
ences (see ESI† for full details) and thus it was anticipated that
other than fluorescence, 4MS would behave in a near identical
fashion to the parent.
Fig. 1 Structure of scriptaid (1) and the fluorescent 4MS. Regions of the
HDAC pharmacophore are also indicated.
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To construct 4MS, 4-bromonaphthalimide 2 (see ESI† for
synthesis) was converted to the corresponding 4-morpholino
derivative 3 using a palladium mediated Buchwald–Hartwig
approach (Scheme 1).8 Treatment of 4-bromonaphthalimide 3
with morpholine (3 equiv.), Pd2(dba)3CHCl3 (4 mol%) and the
commercially available ligand, Xantphos (4 mol%) in the presence
of Cs2CO3 (3 equiv.) at 40 1C for 24 h gave the desired aryl amine 3
in excellent yield (90%). Carboxylic acid 4 was obtained in high
yield (91%) using excess LiOHH2O. The free acid was converted to
the mixed anhydride (using ClCO2Et and Et3N) then in situ treated
with hydroxylamine (in methanol) to give the desired hydroxamic
acid 4MS in good yield (67%, 50% over 4 steps).
Compound 4MS was then assessed for inhibitory activity
against HDAC isoforms 1, 3 and 8 (class I), 6 (class IIb) and
HDAC 11 (class IV). The introduction of the morpholine group
was not deleterious towards HDAC inhibition. Indeed, when
compared to scriptaid (1), 4MS had similar activity against both
HDAC6 (IC50 = 12 nM, Table 1) and HDAC3 (4MS, IC50 = 0.32 mM;
cf. 1, IC50 = 0.37 mM) and was slightly more eﬃcacious against
HDAC1 (IC50 = 1.43 mM) than scriptaid (1, IC50 = 1.74 mM). As
such, 4MS displayed a similar selectivity profile to that of
scriptaid (1) for HDAC6 over HDAC1 and HDAC3. For the other
class I isoform investigated (HDAC8) 4MS inhibited with an
IC50 of 1.81 mM compared with 1.52 mM for 1 which corresponds
to improved selectivity (4MS, SF = 151; cf. 1, SF = 127). A moderate
improvement in activity was also obtained at HDAC11 (4MS,
IC50 = 0.29 mM; cf. 1, IC50 = 0.36 mM).
Both scriptaid (1) and 4MS exhibit modest selectivity towards
HDAC6, which is known to modulate a number of cytosolic
processes that can lead to cell stress and apoptosis including
a-tubulin deacetylation and binding to the stress granule protein,
G3PB1.9 Indeed, HDAC6 inhibitors have been proposed as
therapies for acute myeloid leukemia,10 a hematological cancer
represented by KASUMI-1 cells. As such the ability of 4MS to
decrease cell growth was evaluated in KASUMI-1 cells (Table 1) and
4MS inhibited the growth of the leukemia cell line with an IC50 of
0.29 mM, which is comparable with scriptaid (1, IC50 = 0.49 mM).
The photophysical properties of 4MS were typical of 4-dialkyl-
amino-1,8-naphthalimide derivatives11 and proved to be well suited
for fluorescence microscopy. In DMSO, the absorption maximum
(Fig. 2) was 399 nm with an emission maximum at 534 nm (Stokes
shift = 135 nm). This compares favourably with scriptaid (1), which
presents no visible fluorescence.
To demonstrate the potential of 4MS as a tool to provide
pharmacokinetic information, confocal microscopy was used
to visualise the cellular penetration and subcellular location of
4MS in the human breast cancer MDA-MB-231 cell line. The cells
were treated in situ with a 1.0 mM solution of 4MS and images
were taken at 10 second time points (Fig. 3A–F). At each time
point, a significant increase in emission intensity from the treated
cells was evident, clearly indicating rapid cellular uptake.
Scheme 1 Synthesis of 4MS.
Table 1 Inhibition of individual HDAC isoforms, IC50 (mM)
Compound
HDAC isoform (SF), SF = selectivity factor vs. HDAC6
KASUMI-11 3 6 8 11
Scriptaid (1) 1.74  0.06a (145) 0.37  0.06 (31) 0.012  0.0026 1.52  0.01 (127) 0.36  0.03 (30) 0.49b
4MS 1.43  0.13 (119) 0.32  0.04 (27) 0.012  0.0019 1.81  0.17 (151) 0.29  0.02 (24) 0.29
a Values represent the average of two measurements (n = 2). b Error o 1% (n = 3).
Fig. 2 Normalised excitation and emission spectra of 4MS in DMSO.
Fig. 3 Confocal microscopy images of MDA-MB-231 cells showing the
rapid cellular uptake of 4MS at 1.0 mM. Images are of the following time
points: (A) 0 s, (B) 10 s, (C) 20 s, (D) 30 s, (E) 40 s, (F) 50 s.
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Cellular uptake of biologically active molecules is currently
generally monitored by radio-labelling or fluorescent tagging.12
While radio-labelling can be achieved through isotopic replace-
ment it requires specialised equipment and precautions. As
mentioned, fluorescent tagging often leads to a significant
increase in the molecular weight of the known biologically
active compound. Large increases in molecular weights may
result in poor absorption and cell permeation of the fluorescent
therapeutic.13 By utilising the inherent fluorescent properties
of 4MS, rapid cellular uptake was visualised in less than
50 seconds.
Additional time course studies were conducted at lower
concentrations (0.025–0.30 mM), in which 4MS was incubated
in MDA-MB-231 cells for 48 h and co-stained with propidium
iodide to monitor cell death (Fig. 4). No fluorescence was
observed in the nucleus, suggesting that 4MS did not penetrate
the nuclear envelope. It is possible that the lack of observed
fluorescence in the nucleus was due to DNA mediated fluores-
cence quenching rather than lack of penetration therefore
titrations of 4MS with calf thymus (ct)-DNA were conducted.
While a slight decrease in the emission intensity of 4MS was
observed upon the addition of ct-DNA in phosphate buffer
(10 mM at pH 7.4), the emission band of 4MS was still clearly
visible after a large excess of ct-DNA had been added (see ESI†).
These results indicate that 4MS was not entering the nucleus
and that the lack of fluorescence emission from the nucleus
was not a result of DNA binding/quenching. The observed
cytoplasmic accumulation is interesting given the concen-
tration of HDACs in the nucleus and may ultimately prove
advantageous as the class II HDAC isoforms, such as HDAC6,
are known to shuttle between the nucleus and the cytoplasm
and mediate processes such as a-tubulin deacetylation.14
Based on our results, it might be possible to design selective
inhibitors for class II HDAC by refining the localisation profile
of the therapeutic rather than focussing solely on enhancing its
specific enzyme binding.
Upon incubation of MDA-MB-231 cells with the fluorescent
4MS at 0.025 and 0.1 mM no significant changes were observed
(Fig. 4A and B, respectively). However, the treatment of MDA-
MB-231 cells with 0.3 mM 4MS, cell death was evident within
48 h (Fig. 4C).
In summary, the rational design and synthesis of 4MS has
been performed. Structural changes from scriptaid (1) were
minimal and were not detrimental to isoform selectivity or
anticancer activity (KASUMI-1). The strategic location of the
morpholino substituent at the 4-position of the naphthalimide
imparted photophysical properties and enabled the study of these
compounds in cells using fluorescence microscopy; demonstrated
with the visualisation of rapid cellular uptake and subsequent
distribution in MDA-MB-231 cells. This fluorescent analogue
has very quickly contributed to our understanding of how the
well-studied scriptaid (1) acts at a cellular level and is likely to
be a value to the many researchers currently investigating scriptaid
(1) as a potential neuroprotectant and anticancer agent.
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